Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program (ESP)

Medical University of Vienna

Status: Unknown

Conditions: Kidney Function After Transplantation; Outcome After Kidney Transplantation

Study type: Observational

Funder types: Other

Identifiers

NCT00461357

NTX-OFO-01

Details and patient eligibility

About

The Eurotransplant Senior Program (ESP) started in 1999 with local allocation of kidneys from deceased donors elder than 65 years to recipients elder than 65 years. The requirements for immunosuppression in this group of patients are high due to the large amount of comorbidities.

This prospective randomized trial compared the standard immunosuppressive protocol based on cyclosporine A (CyA) used at our center within the ESP, to a calcineurin inhibitor-free protocol based on sirolimus (SRL).

The aim of this study is to investigate the effect of a CNI-free therapy on the function of elderly kidneys 6 months post transplantation, measured by GFR.

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recipients of the Eurotransplant Senior Program
• negative cytotoxic crossmatch
• signed informed consent

Exclusion criteria

• High sensitized recipients (PRA > 40%)
• Non heart Beating Donor
• Hyperlipidemia
• Leucocytopenia (< 3000/mm3)
• Thrombocytopenia (< 75000/mm3)